[go: up one dir, main page]

PL380665A1 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
PL380665A1
PL380665A1 PL380665A PL38066504A PL380665A1 PL 380665 A1 PL380665 A1 PL 380665A1 PL 380665 A PL380665 A PL 380665A PL 38066504 A PL38066504 A PL 38066504A PL 380665 A1 PL380665 A1 PL 380665A1
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
disclosed
useful pharmaceutical
compositions
pharmaceutical
Prior art date
Application number
PL380665A
Other languages
Polish (pl)
Inventor
Susan K. Heimbecher
Jim H. Kou
Irina Kazakevich
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of PL380665A1 publication Critical patent/PL380665A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are useful pharmaceutical compositions.
PL380665A 2003-12-19 2004-12-17 Pharmaceutical compositions PL380665A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53156103P 2003-12-19 2003-12-19

Publications (1)

Publication Number Publication Date
PL380665A1 true PL380665A1 (en) 2007-03-05

Family

ID=34710234

Family Applications (1)

Application Number Title Priority Date Filing Date
PL380665A PL380665A1 (en) 2003-12-19 2004-12-17 Pharmaceutical compositions

Country Status (15)

Country Link
US (3) US20060009504A1 (en)
EP (1) EP1701699B1 (en)
JP (1) JP2007514758A (en)
KR (1) KR20060111581A (en)
CN (1) CN100528162C (en)
AT (1) ATE516011T1 (en)
AU (1) AU2004303425C1 (en)
BR (1) BRPI0417205A (en)
CA (1) CA2550071A1 (en)
MX (1) MXPA06007102A (en)
NO (1) NO20063293L (en)
NZ (1) NZ547557A (en)
PL (1) PL380665A1 (en)
WO (1) WO2005060981A2 (en)
ZA (1) ZA200604874B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2528669T3 (en) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
TWI489984B (en) 2006-08-04 2015-07-01 Wyeth Corp Formulations for parenteral delivery of compounds and uses thereof
US20090041839A1 (en) * 2007-05-23 2009-02-12 Beasley Martin W Pharmaceutical compositions for the treatment of pain
SE531698C2 (en) 2007-07-12 2009-07-07 Respiratorius Ab New bronchodilating a, b unsaturated amides
SG10201501821RA (en) 2010-03-11 2015-05-28 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone
WO2012127472A1 (en) * 2011-03-22 2012-09-27 Mapi Pharma Ltd. Process and intermediates for the preparation of preladenant and related compounds
CN106365221B (en) * 2016-11-09 2019-04-19 烟台史密得机电设备制造有限公司 A kind of adamantane mono-quaternaries cationic ternary composite flooding water extraction degreaser
EA201992595A1 (en) 2017-05-05 2020-04-21 Фьюжн Фармасьютикалс Инк. STRENGTHENING OF PHARMACOKINETICS OF BIFUNCTIONAL CHELATES AND THEIR APPLICATION
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
KR20200004861A (en) 2017-05-05 2020-01-14 퓨전 파마슈티칼즈 인크. IGF-1R monoclonal antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656028A (en) * 1986-06-24 1987-04-07 Norcliff Thayer Inc. Encapsulated antacid
US5935584A (en) * 1994-01-13 1999-08-10 Elizabeth Arden Company Vitamin C delivery system
ATE364374T1 (en) * 1997-08-11 2007-07-15 Pfizer Prod Inc SOLID PHARMACEUTICAL DISPERSIONS WITH INCREASED BIOAVAILABILITY
US6326390B1 (en) * 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6921825B2 (en) * 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
MXPA01011981A (en) * 1999-05-24 2003-09-04 Sonus Pharma Inc Emulsion vehicle for poorly soluble drugs.
JP4100865B2 (en) * 1999-12-13 2008-06-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 Tricyclic fused heterocyclic compound, process for producing the same and medicament
IL152726A0 (en) * 2000-05-26 2003-06-24 Schering Corp Adenosine a2a receptor antagonists
AR037243A1 (en) * 2001-10-15 2004-11-03 Schering Corp ADENOSINE RECEIVER ANTAGONISTS A2A, A5-AMINO-IMIDAZOLO- [4,3-E] -1,2,4-TRIAZOL- [1,5-C] PYRIMIDINE, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF A MEDICINAL PRODUCT
HUP0402018A3 (en) * 2001-11-30 2008-06-30 Schering Corp 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them
HK1082662A1 (en) * 2002-05-30 2006-06-16 King Pharmaceuticals Research And Development Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same

Also Published As

Publication number Publication date
EP1701699B1 (en) 2011-07-13
EP1701699A2 (en) 2006-09-20
WO2005060981A3 (en) 2005-12-29
CN1893921A (en) 2007-01-10
US20110207740A1 (en) 2011-08-25
KR20060111581A (en) 2006-10-27
ZA200604874B (en) 2007-03-28
WO2005060981A2 (en) 2005-07-07
MXPA06007102A (en) 2006-08-23
BRPI0417205A (en) 2007-02-06
NZ547557A (en) 2010-07-30
US20080293734A1 (en) 2008-11-27
AU2004303425B2 (en) 2009-03-26
JP2007514758A (en) 2007-06-07
ATE516011T1 (en) 2011-07-15
US20060009504A1 (en) 2006-01-12
NO20063293L (en) 2006-07-14
CN100528162C (en) 2009-08-19
AU2004303425A1 (en) 2005-07-07
AU2004303425C1 (en) 2010-02-18
CA2550071A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
GB2389530B (en) Pharmaceutical compositions
GB0320382D0 (en) Pharmaceutical compositions
GB0327723D0 (en) Pharmaceutical compositions
SG145694A1 (en) Novel compounds
GB0301554D0 (en) Immunostimulatory compositions
LUC00065I2 (en)
UA90875C2 (en) Sustained release pharmaceutical formulations comprising ranolazine
GB2391473B (en) Pharmaceutical compositions
GB0300531D0 (en) Pharmaceutical compositions
EP1648411A4 (en) Pharmaceutical compositions
MX2007007613A (en) Pharmaceutical formulations.
TW200531686A (en) Pharmaceutical compositions
ZA200604874B (en) Pharmaceutical compositions
GB0213481D0 (en) Pharmaceutical compositions
EP1655029A4 (en) Medicinal compositions
EP1480649A4 (en) Stable pharmaceutical compositions
HU0304095D0 (en) Novel, effective pharmaceutical compositions
GB0324574D0 (en) Novel compositions
GB0305579D0 (en) Pharmaceutical compositions
PL370907A1 (en) Pharmaceutical compositions
HK1092712A (en) Pharmaceutical compositions
HK1092702A (en) Pharmaceutical compositions
GB0321611D0 (en) Pharmaceutical compositions
GB0308633D0 (en) Pharmaceutical compositions
GB0310783D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)